Major histocompatibility complex, class I, W (HLA-W)

There is no functional protein or receptor named "major histocompatibility complex, class I, W" (abbreviated as "HLA-W") in the well-established human leukocyte antigen (HLA) system. "HLA-W" is annotated as a pseudogene, meaning it does not encode a protein product and is not involved in antigen presentation or immune modulation like the functional MHC class I genes HLA-A, HLA-B, HLA-C, nor the minor/lower expressed forms such as HLA-E, -F, and -G. As such, it is not considered a therapeutic or diagnostic target in immunology, oncology, transplantation, or other fields. Any entry using "HLA-W" as a target for drug discovery or immunological characterization is therefore incorrect or misleading[7]. Key clarification: - HLA-W is a pseudogene and does NOT encode a functional receptor or MHC class I molecule, unlike HLA-A, B, C, E, F, or G[7]. - It does not participate in biological processes such as antigen presentation, immune response, or disease pathogenesis. - There are no known drugs, biomarkers, or safety concerns associated with HLA-W, as it does not produce a functional protein[7]. - All therapeutic, diagnostic, and mechanistic data related to MHC class I function pertain to other well-characterized proteins in the family, not HLA-W[2][5][6][8]. If you are seeking information on therapeutic targets within the human MHC class I system, refer to HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, or HLA-G.

Other names

HLA-W pseudogeneMajor histocompatibility complex, class I, W